Dexamethasone Ineffective for Preventing Pediatric Migraine Relapse

Research Summary

A study published in the journal Headache explored if intravenous dexamethasone could prevent migraine relapse in children and adolescents discharged from the emergency department. Conducted at the CHU Sainte-Justine in Montréal, 116 participants aged 8-17 were randomized to receive either dexamethasone or a placebo alongside standard migraine therapy. The study found that relapse rates within 48 hours were similar between the dexamethasone group (39%) and placebo group (44%). No significant differences were observed in pain scores, return to school, or healthcare visits. Adverse events were mild and infrequent. These results suggest dexamethasone may not be effective for this purpose.

Study Details

📄 Title: Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department.

👥 Research Team: Tourigny-Ruel G et al.

📚 Published In: Headache

📅 Publication Date: 2026 Apr 3

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.